Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 4

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 3Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms, Male 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × HER2 peptide (369-377) × Clear all
NCT02297698 2023-12-12

HER3+

Cancer Insight, LLC

Phase 2 Completed
100 enrolled 11 charts
Breast

Breast Neoplasms

NCT02636582 2023-12-05

Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
43 enrolled 10 charts
Breast

Carcinoma, Intraductal, Noninfiltrating

NCT01570036 2020-12-02

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

Cancer Insight, LLC

Phase 2 Completed
275 enrolled 23 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01479244 2017-02-27

PRESENT

Galena Biopharma, Inc.

Phase 3 Completed
758 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡